GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005116851 | Stomach | SIM | nuclear export | 14/708 | 154/18723 | 2.16e-03 | 2.26e-02 | 14 |
GO:009015011 | Stomach | SIM | establishment of protein localization to membrane | 20/708 | 260/18723 | 2.18e-03 | 2.27e-02 | 20 |
GO:00723324 | Stomach | SIM | intrinsic apoptotic signaling pathway by p53 class mediator | 9/708 | 76/18723 | 2.23e-03 | 2.30e-02 | 9 |
GO:00327572 | Stomach | SIM | positive regulation of interleukin-8 production | 8/708 | 62/18723 | 2.24e-03 | 2.31e-02 | 8 |
GO:19020415 | Stomach | SIM | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 7/708 | 49/18723 | 2.31e-03 | 2.36e-02 | 7 |
GO:00506703 | Stomach | SIM | regulation of lymphocyte proliferation | 18/708 | 225/18723 | 2.32e-03 | 2.36e-02 | 18 |
GO:00329442 | Stomach | SIM | regulation of mononuclear cell proliferation | 18/708 | 227/18723 | 2.55e-03 | 2.54e-02 | 18 |
GO:0097202 | Stomach | SIM | activation of cysteine-type endopeptidase activity | 4/708 | 16/18723 | 2.56e-03 | 2.54e-02 | 4 |
GO:00068693 | Stomach | SIM | lipid transport | 27/708 | 398/18723 | 2.58e-03 | 2.55e-02 | 27 |
GO:003133341 | Stomach | SIM | negative regulation of protein-containing complex assembly | 13/708 | 141/18723 | 2.70e-03 | 2.64e-02 | 13 |
GO:003250721 | Stomach | SIM | maintenance of protein location in cell | 8/708 | 65/18723 | 3.03e-03 | 2.92e-02 | 8 |
GO:0042104 | Stomach | SIM | positive regulation of activated T cell proliferation | 5/708 | 27/18723 | 3.08e-03 | 2.94e-02 | 5 |
GO:00511004 | Stomach | SIM | negative regulation of binding | 14/708 | 162/18723 | 3.43e-03 | 3.23e-02 | 14 |
GO:00432804 | Stomach | SIM | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 12/708 | 129/18723 | 3.60e-03 | 3.36e-02 | 12 |
GO:00514382 | Stomach | SIM | regulation of ubiquitin-protein transferase activity | 7/708 | 53/18723 | 3.64e-03 | 3.37e-02 | 7 |
GO:00326405 | Stomach | SIM | tumor necrosis factor production | 15/708 | 181/18723 | 3.73e-03 | 3.41e-02 | 15 |
GO:00326805 | Stomach | SIM | regulation of tumor necrosis factor production | 15/708 | 181/18723 | 3.73e-03 | 3.41e-02 | 15 |
GO:004346731 | Stomach | SIM | regulation of generation of precursor metabolites and energy | 12/708 | 130/18723 | 3.84e-03 | 3.49e-02 | 12 |
GO:00616874 | Stomach | SIM | detoxification of inorganic compound | 4/708 | 18/18723 | 4.06e-03 | 3.66e-02 | 4 |
GO:005160431 | Stomach | SIM | protein maturation | 21/708 | 294/18723 | 4.11e-03 | 3.70e-02 | 21 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AR | SNV | Missense_Mutation | | c.2595N>A | p.Asp865Glu | p.D865E | P10275 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
AR | SNV | Missense_Mutation | | c.1912N>A | p.Leu638Met | p.L638M | P10275 | protein_coding | tolerated(0.07) | benign(0.316) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
AR | SNV | Missense_Mutation | novel | c.1082N>A | p.Ser361Asn | p.S361N | P10275 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1681N>A | p.Leu561Met | p.L561M | P10275 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | | c.1703C>T | p.Ser568Phe | p.S568F | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
AR | SNV | Missense_Mutation | novel | c.2642N>A | p.Leu881Gln | p.L881Q | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AR | SNV | Missense_Mutation | novel | c.585N>T | p.Gln195His | p.Q195H | P10275 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.2718N>T | p.Lys906Asn | p.K906N | P10275 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AR | SNV | Missense_Mutation | novel | c.967N>A | p.Glu323Lys | p.E323K | P10275 | protein_coding | tolerated_low_confidence(0.11) | benign(0.265) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AR | SNV | Missense_Mutation | | c.2462G>T | p.Gly821Val | p.G821V | P10275 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | FLUOCINOLONE ACETONIDE | FLUOCINOLONE ACETONIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 4-CHLOROMERCURIBENZOIC ACID | 4-CHLOROMERCURIBENZOIC ACID | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | agonist | CHEMBL2107067 | TESTOSTERONE UNDECANOATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | DIDECYLDIMETHYLAMMONIUM CHLORIDE | DIDECYLDIMETHYLAMMONIUM CHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | QUININE SULFATE | QUININE SULFATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | NILUTAMIDE | NILUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARN-509 | APALUTAMIDE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | CRUFOMATE | CRUFOMATE | |
367 | AR | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | 2-AMINOFLURENE | CHEMBL84472 | |